Jeito Capital

Ksenija Pavletic is a General Partner and CCO at Jeito with 25+ years in pharma and biotech, previously CEO of PregLem SA, which she led to a successful exit. Part of Jeito's founding team.

Dr. Rafaèle Tordjman, MD PhD, founded Jeito Capital in 2018 after nearly two decades as a life sciences investor, including as partner at Sofinnova Partners. She trained as a physician and researcher in haemato-oncology and founded the W.I.T.H. association.

Eloïse Giroux is a financial controller (contrôleuse de gestion) at Ginkgo Advisor Sàrl. She holds a Master's degree in Contrôle, Comptabilité, Audit from IAE Clermont-Auvergne.

Elaine Caughey is Partner for Business Development and Investor Relations, with 30 years across life sciences funds and pharma, previously Deputy COO at Blackstone Life Sciences and CBO at Kymera Therapeutics.

Magdalena Jonikas is a Partner with 15 years of biopharma strategy, investing and operating experience, previously a Partner at Syncona Ltd. and an Associate Partner at McKinsey.

Mehdi Ainouche, PharmD, is a Partner at Jeito with over a decade in life sciences investment, joining in 2020 as Principal. He was previously an associate in Turenne Capital's healthcare venture team.

Pascal Touchon is an Operating Partner with 35+ years in pharma, previously CEO of Atara Biotherapeutics and Global Head of Cell & Gene at Novartis Oncology. He represents Jeito on the boards of CatalYm and XyloCor Therapeutics.

Sabine Dandiguian is Managing Partner at Jeito Capital with over 30 years in pharma and medical devices, including 20 years at Johnson & Johnson where she led Janssen France and European medical operations.

Sarah Shackelton is Partner for Talent, with two decades building leadership teams and boards in life sciences, previously Chief Talent Officer at Oxford Science Enterprises and a Partner at Abingworth.

Anastasiya Sybirna, PhD, is a Principal with biopharma investing and strategy consulting experience, previously a Senior Associate at F-Prime Capital and an Engagement Manager at McKinsey.

Daniel Wolle is a Principal working as Portfolio Manager, previously an Equity Research Analyst at J.P. Morgan covering biotech. He holds a PhD in Molecular Biology from Princeton.

Julien Elric is a Senior Principal focused on deal sourcing and portfolio support, joining Jeito in 2021. He previously led the iPEPS startup incubator at the Paris Brain Institute and holds a PhD from Institut Pasteur.

Maya Chkaiban joined Jeito in January 2020 as a Junior Analyst and progressed to Principal in October 2025. She holds a Doctor of Pharmacy and a Master in Management from ESSEC.

Alain Rougon serves as acting CFO (external provider via Prodensia, which he founded). He previously spent a decade as CFO/Secretary General of investment funds and a decade in audit.

Annette Clancy works on Pharma M&A strategy and is part of Jeito's founding team, with 30+ years of international pharma experience including leading GSK's worldwide transactions and alliance management function.

Benjamin Caillier is Finance Director, joining Jeito in 2023 after 15+ years as CFO of holding companies, investment companies and family offices in France and Luxembourg.

Boris Kere is a Compliance Officer assisting with compliance and internal control, previously a consultant at AGAMA Conseil and in the investment funds department at Dentons Luxembourg.

Charlotte Formont is Senior Legal Counsel, joining Jeito in 2022. She previously worked in the private equity team at Weil Gotshal & Manges (Paris) and is a member of the Paris Bar.

Chloé Morlaàs is Investor Relations Director, previously working in healthcare consulting and a HealthTech association. She holds degrees from ESSEC and the London School of Economics.

Chloé Roche is an Analyst with prior healthcare investment experience in venture capital at Auriga Partners and as a buy-side analyst at DNA Finance. She holds degrees from AgroParisTech and Sciences Po Paris.

Claudio Costa-Neto is Chief Scientific Officer and part of Jeito's founding team, with 25+ years in biomedical sciences across Europe, US and Brazil, including seven years in venture capital and academic leadership at the University of Sao Paulo.

Elana Lockshin is an Analyst who previously worked at Neuro.VC, a San Francisco-based venture capital fund. She holds a PhD in Neurobiology from Duke University.

Elsa Fernandez is Finance Director for the fund, with seven years in healthtech finance including as a consultant at EY advising on IPOs, and prior M&A experience at Pierre Fabre.

Estelle Ruotte is a Finance Manager working on finance monitoring of Jeito funds and portfolio companies, previously a financial auditor at EY specializing in healthcare.

Evaldo Bifulco is Head of Sustainability, Compliance & Risk at Jeito, previously Head of Compliance at ODDO BHF Private Equity and a risk consultant at EY.

Henri Mazeau is a Legal Counsel who previously spent over five years in the private equity team at Weil, Gotshal & Manges (Paris). He is a member of the Paris Bar.

Hortense de Meaux is a Finance Manager in Jeito's finance team, previously a financial auditor at KPMG specializing in the healthtech sector.

Ivana Trivunovic is an Analyst who previously gained healthcare investment experience as a Junior Analyst in the Biofund team at Kurma Partners. She holds a PhD in Neurobiology from the University of Bordeaux.

Karin van Baelen brings over 30 years in global regulatory affairs, having spent nearly a decade as Global Head of Regulatory Affairs at Janssen (Johnson & Johnson).

Manon Frachon is a Project Manager supporting Investor Relations and communications, with prior experience in healthcare investment banking on M&A and financing transactions.

Noémie Timsit is an Associate in the investment team, previously a Junior Analyst Intern, with prior healthcare industry business development experience. She holds a master's in management from ESCP.

Olga Golushko is an Executive Assistant with over four years in a family office and communication firm and prior experience in events agencies. She holds a PhD in Comparative Literature.

Samit Hirawat, M.D., joined Jeito in 2026 as Strategic Medical Advisor. He was previously Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb and Head of Oncology Development at Novartis.

Sarah Oliver Ricome is an Executive Assistant who previously worked at LionTree, a US investment bank in Paris, and at the Fondation Giacometti.

Marco Morelli serves as Chair of the Board of Directors at BNP Paribas Asset Management. In addition to this role, he is a board member, founder of non-profit activities, an academic lecturer, and a writer.

Renaud Dumora is Deputy Chief Operating Officer at BNP Paribas and Head of Investment & Protection Services (IPS), having worked at the firm for 30 years. His current responsibilities include aligning client expectations with social and environmental considerations and applying technologies such as data, AI, platformisation, and APIs across the business. He sponsors "BNP Paribas Ability," an employee mutual-aid network for those affected by disabilities and disabling or chronic illnesses.